StockNews.com Initiates Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX)

StockNews.com started coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research note released on Tuesday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Trading Down 3.0 %

Shares of CPIX stock opened at $1.60 on Tuesday. Cumberland Pharmaceuticals has a 12-month low of $1.43 and a 12-month high of $2.36. The company has a current ratio of 1.28, a quick ratio of 1.11 and a debt-to-equity ratio of 0.44. The firm’s 50 day moving average is $1.88 and its 200 day moving average is $1.88. The stock has a market capitalization of $22.68 million, a P/E ratio of -3.64 and a beta of 0.16.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its earnings results on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 6.84% and a negative net margin of 15.87%. The company had revenue of $9.35 million during the quarter.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp purchased a new stake in Cumberland Pharmaceuticals in the third quarter worth approximately $142,000. Renaissance Technologies LLC raised its position in Cumberland Pharmaceuticals by 6.3% in the first quarter. Renaissance Technologies LLC now owns 644,763 shares of the specialty pharmaceutical company’s stock worth $1,818,000 after acquiring an additional 38,100 shares during the period. Acadian Asset Management LLC raised its position in Cumberland Pharmaceuticals by 27.8% in the first quarter. Acadian Asset Management LLC now owns 188,243 shares of the specialty pharmaceutical company’s stock worth $529,000 after acquiring an additional 40,949 shares during the period. Finally, Millennium Management LLC bought a new position in Cumberland Pharmaceuticals in the fourth quarter worth approximately $46,000. Hedge funds and other institutional investors own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.